A strategy for a rational approach to designing synthetic selective inhibitors.
Hijikata-Okunomiya
A
A
School of Allied Medical Sciences, Kobe University, Japan.
Okamoto
S
S
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives; D001665:Binding Sites; D002091:Butyrylcholinesterase / Q000378:metabolism; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002800:Cholinesterase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D015394:Molecular Structure; D010875:Pipecolic Acids / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014357:Trypsin / Q000378:metabolism; D014361:Trypsin Inhibitors / Q000737:chemistry* / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D010875:Pipecolic Acids; D013449:Sulfonamides; D014361:Trypsin Inhibitors; D001120:Arginine; D002091:Butyrylcholinesterase; D014357:Trypsin; D013917:Thrombin; C031942:argatroban